Nishimura T, Nobuyoshi M
Tracer Kinetics, Osaka University, Medical School.
Kaku Igaku. 1995 Sep;32(9):1007-21.
We performed a multicenter trial of 99mTc-tetrofosmin myocardial SPECT for the assessment of acute thrombolysis, pre and post elective PTCA and myocardial viability in comparison with 201Tl myocardial SPECT. The participants consisted of 212 patients at 44 institutions and the study lasted for 10 months. In assessing acute thrombolysis, the perfusion defect from the acute to subacute phase was reduced by 25% and that from the subacute to chronic phase by 10%. The mean perfusion defect score at subacute and chronic phase was correlated well with regional wall motion. The mean defect score during the subacute phase could predict future wall motion abnormalities. In assessing pre and post PTCA, 99mTc-tetrofosmin stress/rest myocardial SPECT could identify the changes of perfusion as in the case with successful PTCA and/or restenosis. In assessing the myocardial viability, 99mTc-tetrofosmin rest myocardial SPECT was superior to 201Tl redistribution, and equal to 201Tl reinjection method. In summary, we concluded that 99mTc-tetrofosmin is a powerful tool, with which to diagnose and manage patients with coronary artery diseases.
我们进行了一项多中心试验，将99mTc-替曲膦心肌单光子发射计算机断层扫描（SPECT）与201Tl心肌SPECT相比较，用于评估急性溶栓、择期经皮冠状动脉腔内血管成形术（PTCA）前后以及心肌存活性。参与者包括44家机构的212例患者，研究持续了10个月。在评估急性溶栓时，从急性期到亚急性期灌注缺损减少了25%，从亚急性期到慢性期减少了10%。亚急性期和慢性期的平均灌注缺损评分与室壁运动密切相关。亚急性期的平均缺损评分可以预测未来的室壁运动异常。在评估PTCA前后时，99mTc-替曲膦负荷/静息心肌SPECT能够识别出成功PTCA和/或再狭窄情况下的灌注变化。在评估心肌存活性时，99mTc-替曲膦静息心肌SPECT优于201Tl再分布，与201Tl再注射法相当。总之，我们得出结论，99mTc-替曲膦是诊断和治疗冠状动脉疾病患者的有力工具。
